Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS>1 will
recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab
followed by (chemo)radiation.
Phase:
Phase 2
Details
Lead Sponsor:
City Clinical Oncology Hospital No 1
Collaborators:
Moscow City Oncology Hospital No. 62 Moscow Clinical Scientific Center